Exalenz Bioscience Ltd. develops and markets advanced systems that extract vital information for diagnostics from subtle changes in patients’ exhaled breath. Our proprietary core technology enables medical specialists to identify and manage specific digestive and liver conditions with unprecedented ease, patient comfort, and clinical precision.
The company’s flagship product, the BreathID System, answers a long-standing need for fast and accurate assessment and monitoring of diseases of the liver and gastrointestinal tract. It measures parts-per-million changes in the molecular 13C/12C ratio of the patient’s exhaled breath, continuously, automatically, and in real time.
If you are interested in learning more about Exalenz and our medical solutions, please go to www.exalenz.com
